Abstract
Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 954-958 |
| Number of pages | 5 |
| Journal | Clinical Infectious Diseases |
| Volume | 63 |
| Issue number | 7 |
| DOIs | |
| State | Published - Oct 1 2016 |
Keywords
- CRE
- NDM
- bacteremia
- carbapenemase
- ceftazidime-avibactam
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS